Meeting
2018 Genitourinary Cancers Symposium
Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide.
Authors
Emmanuel S. Antonarakis
Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Emmanuel S. Antonarakis , Changxue Lu , Brandon Luber , Hao Wang , Yan Chen , John Silberstein , Danilo Piana , Zhao Lai , Yidong Chen , William B. Isaacs , Jun Luo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 221)
DOI
10.1200/JCO.2018.36.6_suppl.221
Abstract #
221
Poster Bd #
K19
Abstract Disclosures
Similar Posters
First Author: Elena Castro
Poster
2021 Genitourinary Cancers Symposium
Real-world comparison of abiraterone (A) versus enzalutamide (E) for first-line therapy of metastatic castration-resistant prostate cancer (mCRPC).
First Author: Juan Rodrigo Briones Carvajal
Poster
2021 Genitourinary Cancers Symposium
Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
First Author: Howard I. Scher
Poster
2020 ASCO Virtual Scientific Program
HSD3B1 (1245A>C) polymorphism and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (AA) and enzalutamide (ENZA): Results from two prospective studies.
First Author: Isabel Aragon